[{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ubenimex","moa":"||immunostimulants","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2||Receptor protein-tyrosine kinase erbB-2 | Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Huashan Hospital","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Huashan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huashan Hospital \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Huashan Hospital \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"National Cancer Center, Korea","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Center, Korea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center, Korea \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Center, Korea \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"GBG Forschungs GmbH","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"GBG Forschungs GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBG Forschungs GmbH \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"GBG Forschungs GmbH \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Centre L\u00e9on B\u00e9rard","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Centre L\u00e9on B\u00e9rard","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre L\u00e9on B\u00e9rard \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Centre L\u00e9on B\u00e9rard \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Intergroupe Francophone de Cancerologie Thoracique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Intergroupe Francophone de Cancerologie Thoracique","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Boehringer Ingelheim GmbH | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Netherlands Cancer Institute \/ Boehringer Ingelheim GmbH | Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"The Netherlands Cancer Institute \/ Boehringer Ingelheim GmbH | Merck Group"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"AstraZeneca | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Netherlands Cancer Institute \/ AstraZeneca | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ AstraZeneca | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Chordoma Foundation | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Chordoma Foundation | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Leiden University Medical Center \/ Chordoma Foundation | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Region Skane","sponsor":"Swedish Lung Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Region Skane","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region Skane \/ Swedish Lung Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Region Skane \/ Swedish Lung Cancer Study Group"},{"orgOrder":0,"company":"University College, London","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University College, London \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"University College, London \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"University College, London","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University College, London \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"University College, London \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity","highestDevelopmentStatusID":"7","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Nephrology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Ecog-Acrin Cancer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Ecog-Acrin Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecog-Acrin Cancer Research Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ecog-Acrin Cancer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of South Carolina \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Foundation Medicine | Boehringer Ingelheim GmbH | Bayer AG | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Foundation Medicine | Boehringer Ingelheim GmbH | Bayer AG | Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Foundation Medicine | Boehringer Ingelheim GmbH | Bayer AG | Exelixis"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Boehringer Ingelheim GmbH | University of Southern California | Dana-Farber Cancer Institute | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Boehringer Ingelheim GmbH | University of Southern California | Dana-Farber Cancer Institute | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Boehringer Ingelheim GmbH | University of Southern California | Dana-Farber Cancer Institute | US Department of Defense"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"National Comprehensive Cancer Network | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ National Comprehensive Cancer Network | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ National Comprehensive Cancer Network | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Boehringer Ingelheim GmbH | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Boehringer Ingelheim GmbH | Incyte Corporation"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"University of Texas System | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ University of Texas System | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ University of Texas System | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Columbia University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Boehringer Ingelheim GmbH | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Boehringer Ingelheim GmbH | National Comprehensive Cancer Network","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Boehringer Ingelheim GmbH | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Instituto Oncol\u00f3gico Dr. Rosell","sponsor":"Bioven Europe | MFAR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Instituto Oncol\u00f3gico Dr. Rosell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Oncol\u00f3gico Dr. Rosell \/ Bioven Europe | MFAR","highestDevelopmentStatusID":"7","companyTruncated":"Instituto Oncol\u00f3gico Dr. Rosell \/ Bioven Europe | MFAR"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Santosh Kesari","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Santosh Kesari","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Santosh Kesari"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Michael Hopp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Michael Hopp","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Michael Hopp"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jonathan Riess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2 | Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Jonathan Riess","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Jonathan Riess"}]
Find Clinical Drug Pipeline Developments & Deals for Afatinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
